CLAIMS

1. Use of *N*-(1-(3-fluoropropyl)azetidin-3-yl)-6-((6S,8R)-8-methyl-7-(2,2,2-trifluoroethyl)-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolin-6-yl)pyridin-3-amine (AZD9833) in the manufacture of a medicament for treating ER-positive HER2-negative advanced breast cancer in a human or animal patient in need of such treatment, wherein AZD9833 is to be administered to the patient orally once daily at a dose of 75 mg or 150 mg.

2. Use of AZD9833 in the manufacture of a medicament for the treatment of ER-positive HER2-negative advanced breast cancer, wherein the AZD9833 is to be administered orally once daily at a dose between 75 mg and 150 mg.

3. Use of a pharmaceutical composition in the manufacture of a medicament for the treatment of ER-positive HER2-negative advanced breast cancer, wherein the pharmaceutical composition is for once daily oral administration and comprises between 75 mg and 150 mg of AZD9833 and a pharmaceutically acceptable excipient.

4. The use according to claim 3, wherein the amount of AZD9833 is selected from 75 mg and 150 mg.

5. The use according to claim 3 or claim 4, wherein the pharmaceutical composition is in the form of a single tablet.

6. The use according to claim 2, wherein the AZD9833 is to be administered as a single dose unit or as multiple dose units.

7. The use according to claim 6, wherein the AZD9833 is to be administered as a single tablet.

8. The use according to any of claims 2 and 6-7, wherein the AZD9833 is to be administered in combination with a further anti-cancer therapy.

9. The use according to any of claims 2 and 6-8, wherein the AZD9833 is to be administered in combination with palbociclib.

10. The use according to any of claims 2 and 6-8, wherein the AZD9833 is to be administered in combination with an mTOR inhibitor.

11. The use according to claim 10, wherein the AZD9833 is to be administered in combination with everolimus.

12. The use according to any of claims 2 and 6-8, wherein the AZD9833 is to be administered in combination with an AKT inhibitor.

13. The use according to claim 12, wherein the AKT inhibitor is capivasertib.

14. The use according to any of claims 2 and 8-13, wherein the AZD9833 is to be administered to a pre- or post-menopausal woman.

15. The use according to any of claims 2 and 8-14, wherein the cancer has previously been treated with ≥1 endocrine therapy and ≤2 prior chemotherapies for ER-positive HER2-negative advanced breast cancer.

16. The use according to any of claims 2 and 8-15, wherein the AZD9833 is to be administered to a patient whose cancer is resistant to non-steroidal aromatase inhibitors.

17. The use according to any of claims 2 and 8-16, wherein the dose of AZD9833 i) is capable of achieving a mean peak blood plasma concentration in a cancer patient of between 10 and 1000 ng/mL; and/or ii) is capable of achieving a median terminal half-life between 8h and 14h in a cancer patient; and/or iii) is capable of achieving a median terminal half-life of 12h in a cancer patient.

18. The use according to any of claims 2 and 8-17, wherein the dose of AZD9833 is capable of achieving an objective response rate of at least 10%.

19. The use according to any of claims 2 and 8-18, wherein the dose of AZD9833 does not cause any serious side-effects in a cancer patient.